Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
View Digital Edition
Drug Profiles/Updates
Omacetaxine Mepesuccinate: A Novel mRNA Translation Inhibitor for Drug-Resistant Chronic Myelogenous Leukemia
Jacqueline L. Olin, MS, PharmD, BCPS
,
Sabrina W. Cole, PharmD, BCPS
,
Amie J. Dirks-Naylor, PhD
Read More
FDA Oncology Update
Recent Cancer Drugs Approved by the FDA
Read More
Original Article
The Impact of Angiotensin II Receptor Blocker Use in Patients with Prostate Cancer
Lisa Cerutti, PharmD
,
Jacob K. Kettle, PharmD, BCOP
,
Dennis W. Grauer, MS, PhD
Read More
From the Literature
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Read More
Results 1 - 4 of 4